185 related articles for article (PubMed ID: 29233500)
1. Tumor budding is a prognostic factor linked to epithelial mesenchymal transition in pancreatic ductal adenocarcinoma. Study report and literature review.
Chouat E; Zehani A; Chelly I; Njima M; Maghrebi H; Bani MA; Njim L; Zakhama A; Haouet S; Kchir N
Pancreatology; 2018 Jan; 18(1):79-84. PubMed ID: 29233500
[TBL] [Abstract][Full Text] [Related]
2. Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma.
Kohler I; Bronsert P; Timme S; Werner M; Brabletz T; Hopt UT; Schilling O; Bausch D; Keck T; Wellner UF
J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():78-84. PubMed ID: 25827809
[TBL] [Abstract][Full Text] [Related]
3. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma.
O'Connor K; Li-Chang HH; Kalloger SE; Peixoto RD; Webber DL; Owen DA; Driman DK; Kirsch R; Serra S; Scudamore CH; Renouf DJ; Schaeffer DF
Am J Surg Pathol; 2015 Apr; 39(4):472-8. PubMed ID: 25634751
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma.
Wartenberg M; Zlobec I; Perren A; Koelzer VH; Gloor B; Lugli A; Karamitopoulou E
Oncotarget; 2015 Feb; 6(6):4190-201. PubMed ID: 25669968
[TBL] [Abstract][Full Text] [Related]
5. Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma.
Petrova E; Zielinski V; Bolm L; Schreiber C; Knief J; Thorns C; Bronsert P; Timme-Bronsert S; Bausch D; Perner S; Keck T; Wellner U
Virchows Arch; 2020 Apr; 476(4):561-568. PubMed ID: 31786688
[TBL] [Abstract][Full Text] [Related]
6. Tumour budding is a strong and independent prognostic factor in pancreatic cancer.
Karamitopoulou E; Zlobec I; Born D; Kondi-Pafiti A; Lykoudis P; Mellou A; Gennatas K; Gloor B; Lugli A
Eur J Cancer; 2013 Mar; 49(5):1032-9. PubMed ID: 23177090
[TBL] [Abstract][Full Text] [Related]
7. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
[TBL] [Abstract][Full Text] [Related]
8. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
9. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.
Lee SH; Kim H; Hwang JH; Shin E; Lee HS; Hwang DW; Cho JY; Yoon YS; Han HS; Cha BH
Pancreas; 2014 Apr; 43(3):380-8. PubMed ID: 24622067
[TBL] [Abstract][Full Text] [Related]
10. High expression of both desmoplastic stroma and epithelial to mesenchymal transition markers associate with shorter survival in pancreatic ductal adenocarcinoma.
Sánchez-Ramírez D; Medrano-Guzmán R; Candanedo-González F; De Anda-González J; García-Rios LE; Pérez-Koldenkova V; Gutiérrez-de la Barrera M; Rodríguez-Enríquez S; Velasco-Velázquez M; Pacheco-Velázquez SC; Piña-Sánchez P; Mayani H; Gómez-Delgado A; Monroy-García A; Martínez-Lara AK; Montesinos JJ
Eur J Histochem; 2022 Feb; 66(1):. PubMed ID: 35174683
[TBL] [Abstract][Full Text] [Related]
11. Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study.
Karamitopoulou E; Esposito I; Zlobec I; Insilla AC; Wartenberg M; Schaeffer DF; Kalloger S; La Rosa S; Sempoux C; Ramos Centeno I; Lohneis P
Virchows Arch; 2021 Apr; 478(4):719-726. PubMed ID: 33330964
[TBL] [Abstract][Full Text] [Related]
12. Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer.
Galván JA; Zlobec I; Wartenberg M; Lugli A; Gloor B; Perren A; Karamitopoulou E
Br J Cancer; 2015 Jun; 112(12):1944-50. PubMed ID: 25989272
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal-epithelial transition of pancreatic cancer cells at perineural invasion sites is induced by Schwann cells.
Fujii-Nishimura Y; Yamazaki K; Masugi Y; Douguchi J; Kurebayashi Y; Kubota N; Ojima H; Kitago M; Shinoda M; Hashiguchi A; Sakamoto M
Pathol Int; 2018 Apr; 68(4):214-223. PubMed ID: 29457853
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer.
Javle MM; Gibbs JF; Iwata KK; Pak Y; Rutledge P; Yu J; Black JD; Tan D; Khoury T
Ann Surg Oncol; 2007 Dec; 14(12):3527-33. PubMed ID: 17879119
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer.
Bronsert P; Kohler I; Timme S; Kiefer S; Werner M; Schilling O; Vashist Y; Makowiec F; Brabletz T; Hopt UT; Bausch D; Kulemann B; Keck T; Wellner UF
Surgery; 2014 Jul; 156(1):97-108. PubMed ID: 24929761
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes.
Lahat G; Lubezky N; Loewenstein S; Nizri E; Gan S; Pasmanik-Chor M; Hayman L; Barazowsky E; Ben-Haim M; Klausner JM
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S750-7. PubMed ID: 25069861
[TBL] [Abstract][Full Text] [Related]
17. CCL18 promotes epithelial-mesenchymal transition, invasion and migration of pancreatic cancer cells in pancreatic ductal adenocarcinoma.
Meng F; Li W; Li C; Gao Z; Guo K; Song S
Int J Oncol; 2015 Mar; 46(3):1109-20. PubMed ID: 25502147
[TBL] [Abstract][Full Text] [Related]
18. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.
Nishio K; Kimura K; Amano R; Nakata B; Yamazoe S; Ohira G; Miura K; Kametani N; Tanaka H; Muguruma K; Hirakawa K; Ohira M
World J Gastroenterol; 2017 Aug; 23(31):5764-5772. PubMed ID: 28883702
[TBL] [Abstract][Full Text] [Related]
19. Evaluation and prognostic significance of tumor budding in pancreatic ductal adenocarcinomas.
Argon A; Öz Ö; Kebat TA
Indian J Pathol Microbiol; 2023; 66(1):38-43. PubMed ID: 36656208
[TBL] [Abstract][Full Text] [Related]
20. Superior mesenteric artery margin in pancreaticoduodenectomy for pancreatic adenocarcinoma.
Liu DN; Lv A; Tian ZH; Tian XY; Guan XY; Dong B; Zhao M; Hao CY
Oncotarget; 2017 Jan; 8(5):7766-7776. PubMed ID: 27999192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
